KPV: uses, evidence and status | Inside Your Peptides

compound file

The answer, first. The three-residue tail of alpha-melanocyte-stimulating hormone, lysine-proline-valine, identified as an anti-inflammatory fragment in the 1990s and sold since the 2010s. The strongest evidence is for colitis and gut inflammation, graded D — animal or mechanism only.

Oral KPV reduced dextran-sulfate and TNBS colitis in mice, with lower pro-inflammatory cytokine messenger RNA ¹.

Nanomolar KPV blocked NF-kappaB and MAP kinase signalling in human intestinal cells ¹. No human trial. Every other use — colitis-associated tumours, bacterial and fungal killing, mucosal and corneal repair — grade D or E: animal or mechanism data with no controlled human outcome.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 4 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Colitis and gut inflammationno trial · two mouse colitis modelsgrade DOral KPV reduced dextran-sulfate and TNBS colitis in mice, with lower pro-inflammatory cytokine messenger RNA ¹. Nanomolar KPV blocked NF-kappaB and MAP kinase signalling in human intestinal cells ¹. No human trial.

02Colitis-associated tumoursno trial · 1 mouse carcinogenesis modelgrade DKPV prevented carcinogenesis in wild-type mice given azoxymethane and dextran sulfate, and did nothing in PepT1-knockout mice, which pins the effect on the transporter ³. Mice only.

03Bacterial and fungal killingno trial · in vitro onlygrade DKPV inhibited Staphylococcus aureus colony formation and reduced Candida albicans viability and germ-tube formation across a broad concentration range down to picomolar ⁴. Culture plates, no infection model in a person.

04Mucosal and corneal repairno trial · rat and rabbit modelsgrade DA KPV-loaded mucoadhesive hydrogel reduced inflammation and sped repair in chemotherapy-induced oral mucositis in rats ⁵. Separately, alpha-MSH 11-13 accelerated corneal epithelial closure through nitric oxide ⁶. No human trial.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetKPV is alpha-MSH residues 11 to 13. It enters cells through PepT1, the di-tripeptide transporter upregulated in inflamed colon ¹⁹.

2signalAt nanomolar concentrations it blocks NF-kappaB and MAP kinase activation in human intestinal epithelial cells and in T cells ¹.

3effectPro-inflammatory cytokine secretion falls. In mice, colitis severity, weight loss and colonic myeloperoxidase activity all drop ¹².

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

KPV is proven for gut inflammation. Every positive result is mouse, rat or cell culture. FDA states it has identified no human exposure data by any route ⁸.
KPV treats mast cell activation. No published study tests histamine release or mast cell activation as an endpoint in any species.
Injection is the studied route. The colitis work dosed KPV orally, in drinking water or through targeted oral carriers designed to reach the colon ¹⁷.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeReported as oral capsules, subcutaneous injection, and topical creams. The published animal work dosed it orally or delivered it into the colon ¹⁷.

formatLyophilised powder in a vial, or an oral capsule. Also compounded into creams.

published dosesNo human dosing study exists. In the mouse colitis work KPV was added to drinking water, with the anti-inflammatory effect appearing at nanomolar concentrations in the cell assays ¹. Later work raised colonic delivery using hyaluronic-acid-functionalised nanoparticles ⁷. FDA states it has identified no human exposure data on KPV by any route of administration ⁸.

human pharmacokineticsNo human pharmacokinetic data published.

reported conventionsAs reported on gut-health and peptide forums, 2018 to 2026: oral capsules of roughly 250 to 500 micrograms daily for gut complaints. Subcutaneous doses run in a similar range, and topical blends are used for skin. Convention, not guidance.

commonly paired withBPC-157

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetNo trial has measured onset in a person. In mouse colitis, weight regain and lower colonic myeloperoxidase appeared inside the treatment window of the model ². As reported: days to two weeks for gut symptoms. No trial measured that.

most common reportAs reported: quieter gut symptoms within days. Many report nothing at all.

adverse effectsNo human safety trial exists at any dose or route. FDA states it has identified no human exposure data and lacks information on whether KPV would cause harm in people ⁸. As reported: flushing, transient fatigue, injection-site reaction.

the stop signalAs reported: symptoms settling, or the course simply running out. No published stopping rule exists, because no human study has ever run one.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalNot approved anywhere. Sold as a research chemical.

FDACategory 2 on FDA's compounding safety-risk list. The agency states it has identified no human exposure data by any route ⁸.

sport [WADA]Not named. S0 catches any non-approved substance ¹⁰.

sold asresearch chemical

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is KPV used for?

Gut inflammation, mostly. It is also sold for skin and for general anti-inflammatory use. The published record is two mouse colitis models, a mouse colitis-associated cancer model, and a rat oral mucositis model.

Culture-plate work shows it kills Staphylococcus aureus and Candida albicans. Every one of those grades D, because none is a controlled human outcome. No human trial of KPV has ever been published for any indication.

How is KPV used?

Descriptively, and labelled as such. The animal studies gave KPV by mouth, in drinking water or inside nanoparticle carriers built to survive the stomach and release in the colon.

That route was chosen because the transporter that takes it up is upregulated in inflamed gut. As reported on gut-health forums between 2018 and 2026, the convention is oral capsules of roughly 250 to 500 micrograms daily. Some report subcutaneous use in a similar range.

How long does KPV take to work?

No trial has measured that in a person. In the mouse colitis models, treated animals regained weight and showed lower colonic myeloperoxidase. That happened inside the model's treatment window, which runs days to a couple of weeks.

That is a mouse timeline for a mouse disease induced with a chemical. As reported, users describe days to two weeks for gut symptoms. Nothing published tests whether that is the compound.

Is there any human evidence for KPV?

None. Not a trial, not an open-label series, not a case report with a measured endpoint. FDA put it in category 2 on its compounding safety-risk list, with an unusually blunt entry.

The agency has identified no human exposure data on drug products containing KPV administered via any route of administration. It lacks the information to know whether KPV would cause harm in people. The parent hormone alpha-MSH has human data. This fragment does not.

References

Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177
Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID 18092346
Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016. PMID 27458604
Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000. PMID 10670585
In situ mucoadhesive hydrogel capturing tripeptide KPV: anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci. 2021. PMID 34846053
Effects of the COOH-terminal tripeptide alpha-MSH 11-13 on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006. PMID 16965771
Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017. PMID 28143741
FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov
The melanocortin system in inflammatory bowel diseases: insights into its mechanisms and therapeutic potentials. Cells. 2023. PMID 37508552
World Anti-Doping Agency. The Prohibited List, section S0 Non-Approved Substances. wada-ama.org

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.